Emily A. Egusa
Email: egusa002@umn.edu
Entering Class: 2022
Education:Â Â
California State University - Chico
Cellular and Molecular Biology major
Animal Science, Biochemistry and Chemistry minors
B.S., 2018
MSTP Student Governance:
Emily is currently in the second year of Medical School training and is rotating through labs while preparing to select a thesis advisor.
Publications:
For work prior to the UMN MSTP
medRxiv [Preprint]. 2024 Jan 10:2023.05.17.23290140. PMCID: PMC10802642Â
Large tandem duplications in cancer result from transcription and DNA replication collisions.Clin Cancer Res. 2023 Apr 3;29(7):1232-1242. PMCID: PMC10073270Â
Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.Cancer Res. 2023 Jan 18;83(2):301-315. PMCID: PMC10263373Â
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.Clin Cancer Res. 2022 Jul 15;28(14):3066-3075. PMCID: PMC9288514
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.Eur Urol Oncol. 2022 Dec;5(6):714-718. PMCID: PMC10262920
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.Nat Commun. 2021 Jul 29;12(1):4601. PMCID: PMC8322386
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.NECTIN4Â Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 Sep 15;27(18):5123-5130. PMCID: PMC8634828
Heterogeneity inÂIsolation and Characterization of Bacteria that Produce Polyhydroxybutyrate Depolymerases. J Microbiol Biol Educ. 2018 Dec 14;19(3):19.3.106. PMCID: PMC6289828Â